Updates are available Correction dated 2021-10-27
Click to view Correction: https://doi.org/10.1038/s42003-021-02789-5
-
Authors
Losurdo, Agnese
Scirgolea, Caterina http://orcid.org/0000-0001-9213-5532
Alvisi, Giorgia
Brummelman, Jolanda http://orcid.org/0000-0003-3581-4816
Errico, Valentina
Di Tommaso, Luca
Pilipow, Karolina
Colombo, Federico Simone http://orcid.org/0000-0003-4480-3481
Fernandes, Bethania http://orcid.org/0000-0002-4327-1586
Peano, Clelia http://orcid.org/0000-0001-7055-3629
Testori, Alberto
Tinterri, Corrado
Roncalli, Massimo
Santoro, Armando http://orcid.org/0000-0003-1709-9492
Mazza, Emilia Maria Cristina http://orcid.org/0000-0003-2424-3640
Lugli, Enrico http://orcid.org/0000-0002-1964-7678
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG20676)
- License Information
-
More Information
Article History
Received: 9 August 2020
Accepted: 12 August 2021
First Online: 22 September 2021
Change Date: 27 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-021-02789-5
Competing interests
: The Laboratory of Translational Immunology receives reagents in kind as part of a collaborative research agreement with BD Biosciences (Italy). A.S. has received honoraria as advisory board member from Bristol-Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, and Merck Sharp & Dhome; as speaker’s bureau member from Takeda, Roche, Abbvie, Amgen, Celgene, Astrazeneca, Lilly, Sandoz, Novartis, Bristol-Myers Squibb, Servier, Gilead, Pfizer, Arqule, and Eisai; and for consultancy from Arqule. All other authors declare no competing interests.
